Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2020
Subjects:
Immunobiology and Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556133/
https://ncbi.nlm.nih.gov/pubmed/33035333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002394
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items